| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5045552 | WOODWARD | Pyridine derivatives having anti-ulcerative activity |
May, 2013
(11 years ago) | |
|
US5045552 (Pediatric) | WOODWARD | Pyridine derivatives having anti-ulcerative activity |
Nov, 2013
(10 years ago) | |
Aciphex is owned by Woodward.
Aciphex contains Rabeprazole Sodium.
Aciphex has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Aciphex are:
- US5045552
- US5045552*PED
Aciphex was authorised for market use on 29 May, 2002.
Aciphex is available in tablet, delayed release;oral dosage forms.
Aciphex can be used as treatment of peptic ulcers.
The generics of Aciphex are possible to be released after 08 November, 2013.
Drugs and Companies using RABEPRAZOLE SODIUM ingredient
Market Authorisation Date: 29 May, 2002
Treatment: Treatment of peptic ulcers
Dosage: TABLET, DELAYED RELEASE;ORAL
How can I launch a generic of ACIPHEX before it's drug patent expiration?
More Information on Dosage
ACIPHEX family patents
